Home Careers Contact

Price: 4.05

Change: 0.00

Day High: 4.15
Day Low: 3.96
Volume: 980,462

4:00 PM ET | Mar 22, 2017
Delayed 20 min., by eSignal.



Shareholder Tools

Press Releases

Company News
View Summary Cempra's Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
Aug 25, 2016
PDF 17.0 KB Add to Briefcase
View Summary Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
Aug 23, 2016
PDF 15.9 KB Add to Briefcase
View Summary Cempra Appoints Dr. David Zaccardelli to Board of Directors
Aug 11, 2016
PDF 15.8 KB Add to Briefcase
View Summary Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Aug 1, 2016
PDF 27.8 KB Add to Briefcase
View Summary Cempra Appoints John Bluth Executive Vice President, Investor Relations and Corporate Communications
Aug 1, 2016
PDF 15.8 KB Add to Briefcase
View Summary Cempra to Report Second Quarter 2016 Financial Results
Jul 25, 2016
PDF 11.7 KB Add to Briefcase
View Summary Cempra Announces FDA Acceptance of Solithera™ New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia
Jul 5, 2016
PDF 14.7 KB Add to Briefcase
View Summary Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
Jun 28, 2016
PDF 14.1 KB Add to Briefcase
View Summary Cempra to Host Analyst and Investor Day on June 23, 2016
Jun 16, 2016
PDF 12.1 KB Add to Briefcase
View Summary Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
Jun 10, 2016
PDF 13.7 KB Add to Briefcase
Showing 21-30 of 226 Page: 1 2 3 4 5 6 7 ... 23  Previous 10 | Next 10
Add to Briefcase = add release to Briefcase